Replies to post #47990 on Biotech Values

[Nerf]

Bioneophyte

I don't think that alone RPRX would be worth 20B because they don't have the support structure in place to make such sales a reality.

As a pipeline company they're going to sell their compounds. Androxal is a 200M Euro drug and a $4-500 M Worldwide drug if it gains US approval. They'll only get miletones and royalties. So it's a much smaller value than if they had the option of keeping it.

Same goes for Proellex.

Their potential revenues are huge. their sales price will be nowhere near 20B and they will sell within a year- 1.5 outside IMO.

settle down with the pumping :) A Billion is enough for me.